An Open-Label Extension Study of APD811-003 in Patients With Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals
- 04 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 10 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Nov 2014 New trial record